Latest Clinical News

Nearly half of U.S. men actively infected with HPV, study finds HPV-linked cancers on the rise in men, but nearly 9 in 10 vaccine-eligible men are unvaccinated! (02-20-2017)

By Rachel Tompa / Fred Hutch News Service The most common sexually transmitted infection in the U.S. has a bit of a twist. It’s what’s known as a “subclinical infection” — those infected suffer no immediate consequences, but years later have... Continue Reading

Proton beam therapy may improve outcomes for pancreatic cancer (02-17-2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

FDA Approves Opdivo for Treatment of Bladder Cancer (02-16-2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing... Continue Reading

Vaccine Shows Promising Results for Early-Stage Breast Cancer Patients (02-15-2017)

Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patient’s own immune system to fight and kill cancer. Doctors at Moffitt Cancer Center in Tampa Florida are working on a promising new vaccine that... Continue Reading

Twice-daily radiation therapy reduces mortality from head and neck cancer (02-14-2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with... Continue Reading

Imbruvica® is approved by FDA for Marginal Zone Lymphoma (02-7-2017)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. These data were... Continue Reading

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer (02-6-2017)

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer... Continue Reading

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (02-3-2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were published in The Lancet Oncology, and presented at... Continue Reading

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma (01-31-2017)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately... Continue Reading

Drug Payment Assistance Programs for Cancer (01-25-2017)

Great advances have been made in the drug treatment of cancer leading to improved cure rates and longer survival. Managing a life threatening or chronic disease, cancer is difficult enough to begin with and can be made much more difficult if you are unable... Continue Reading

Many Late Stage Lung Cancer Patients do not Receive Treatment (01-24-2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading

Scientific Highlights from American Society of Hematology Meeting (01-24-2017)

About CAR-T CAR-T, or chimeric antigen receptor T-cells, is a new form of cancer immunotherapy in which a patient’s own T cells are removed and then engineered to identify and kill malignant multiple myeloma cells. The use of a patient’s own immune... Continue Reading

Next Page »